Table 4 Effectiveness of the ChAdOx1-S and BNT162b2 booster vaccines against hospitalisation as defined by linkage to the secondary care (SUS) data following infection with Delta or Omicron variants in adults aged 65 years and older in England
Dose | Booster manufacturer | Interval (days) | Controls | Cases | ORa | VEb (95% CI) |
|---|---|---|---|---|---|---|
Delta | ||||||
Unvaccinated | 1327 | 2000 | Baseline | Baseline | ||
Dose 2c | 175+ | 7000 | 3248 | 0.27 (0.24–0.3) | 73.4 (70.4–76.2) | |
Booster | Anyd | 0–6 | 1123 | 243 | 0.13 (0.11–0.16) | 86.8 (83.7–89.2) |
BNT162b2 | 7+ | 7884 | 355 | 0.06 (0.05–0.07) | 93.9 (92.8– 94.9) | |
ChAdOx1-S | 7+ | 43 | 4 | 0.19 (0.04–0.84) | 80.9 (15.6– 95.7) | |
Omicron | ||||||
Unvaccinated | 517 | 603 | Baseline | Baseline | ||
Dose 2c | 175+ | 1596 | 430 | 0.39 (0.3–0.5) | 61.0 (49.8–69.7) | |
Booster | Anyd | 0–6 | 361 | 27 | 0.24 (0.13-0.45) | 75.5 (54.9– 86.7) |
BNT162b2 | 7+ | 6495 | 953 | 0.09 (0.07–0.11) | 90.9 (88.7– 92.7) | |
ChAdOx1-S | 7+ | 52 | 18 | 0.18 (0.09–0.36) | 82.3 (64.2– 91.3) | |
